1. Chromosomes and Gene Expression

An anciently diverged family of RNA binding proteins maintain correct splicing of a class of ultra-long exons through cryptic splice site repression

  1. Chileleko Siachisumo
  2. Sara Luzzi  Is a corresponding author
  3. Saad Aldalaqan
  4. Gerald Hysenaj
  5. Caroline Dalgliesh
  6. Kathleen Cheung
  7. Matthew R Gazzara
  8. Ivaylo D Yonchev
  9. Katherine James
  10. Mahsa Kheirollahi Chadegani
  11. Ingrid E Ehrmann
  12. Graham R Smith
  13. Simon J Cockell
  14. Jennifer Munkley
  15. Stuart A Wilson
  16. Yoseph Barash
  17. David J Elliott  Is a corresponding author
  1. Biosciences Institute, Faculty of Medical Sciences, Newcastle University, United Kingdom
  2. Bioinformatics Support Unit, Faculty of Medical Sciences, Newcastle University, United Kingdom
  3. Department of Genetics, Perelman School of Medicine, University of Pennsylvania, United States
  4. School of Biosciences, University of Sheffield, United Kingdom
  5. School of Computing, Newcastle University, United Kingdom
https://doi.org/10.7554/eLife.89705.3
Share this article
Cite this article
  1. Chileleko Siachisumo
  2. Sara Luzzi
  3. Saad Aldalaqan
  4. Gerald Hysenaj
  5. Caroline Dalgliesh
  6. Kathleen Cheung
  7. Matthew R Gazzara
  8. Ivaylo D Yonchev
  9. Katherine James
  10. Mahsa Kheirollahi Chadegani
  11. Ingrid E Ehrmann
  12. Graham R Smith
  13. Simon J Cockell
  14. Jennifer Munkley
  15. Stuart A Wilson
  16. Yoseph Barash
  17. David J Elliott
(2024)
An anciently diverged family of RNA binding proteins maintain correct splicing of a class of ultra-long exons through cryptic splice site repression
eLife 12:RP89705.
https://doi.org/10.7554/eLife.89705.3
  2. Download BibTeX
  3. Download .RIS

Abstract

Previously, we showed that the germ cell-specific nuclear protein RBMXL2 represses cryptic splicing patterns during meiosis and is required for male fertility (Ehrmann et al., 2019). Here, we show that in somatic cells the similar yet ubiquitously expressed RBMX protein has similar functions. RBMX regulates a distinct class of exons that exceed the median human exon size. RBMX protein-RNA interactions are enriched within ultra-long exons, particularly within genes involved in genome stability, and repress the selection of cryptic splice sites that would compromise gene function. The RBMX gene is silenced during male meiosis due to sex chromosome inactivation. To test whether RBMXL2 might replace the function of RBMX during meiosis we induced expression of RBMXL2 and the more distantly related RBMY protein in somatic cells, finding each could rescue aberrant patterns of RNA processing caused by RBMX depletion. The C-terminal disordered domain of RBMXL2 is sufficient to rescue proper splicing control after RBMX depletion. Our data indicate that RBMX and RBMXL2 have parallel roles in somatic tissues and the germline that must have been conserved for at least 200 million years of mammalian evolution. We propose RBMX family proteins are particularly important for the splicing inclusion of some ultra-long exons with increased intrinsic susceptibility to cryptic splice site selection.

eLife assessment

This important paper addresses the process by which cryptic splice sites that occur randomly in exons are ignored by the splicing machinery. Integrating state-of- the-art genome-wide approaches such as CLIP-seq with the study of individual examples, this study convincingly implicates members of RBMX family of RNA binding proteins in such cryptic splice site suppression and showcases its importance for the fidelity of expression of genes with very large exons.

https://doi.org/10.7554/eLife.89705.3.sa0

Introduction

Efficient gene expression in eukaryotes requires introns and exons to be correctly recognised by the spliceosome, the macromolecular machine that joins exons together. The spliceosome recognises short sequences called splice sites that are present at exon-intron junctions within precursor mRNAs. In higher organisms, there is some flexibility in splice site recognition, as most genes produce multiple mRNAs by alternative splicing. However, aberrant ‘cryptic’ splice sites that are weakly selected or totally ignored by the spliceosome occur frequently in the human genome and can function as decoys to interfere with gene expression (Aldalaqan et al., 2022; Sibley et al., 2016). Many cryptic splice sites are located amongst repetitive sequences within introns, where they are repressed by RNA-binding proteins belonging to the hnRNP family (Attig et al., 2018). However, cryptic splice sites can also be present within exons, and particularly can shorten long exons (by providing competing alternative splice sites) or cause the formation of exitrons (internal exon sequences that are removed as if they were introns) (Marquez et al., 2015).

The testis-specific nuclear RNA binding protein RBMXL2 was recently shown to repress cryptic splice site selection during meiosis, including within some ultra-long exons of genes involved in genome stability (Ehrmann et al., 2019). RBMXL2 is only expressed within the testis (Aldalaqan et al., 2022; Ehrmann et al., 2019), raising the question of how these same cryptic splice sites controlled by RBMXL2 are repressed in other parts of the body. Suggesting a possible answer to this question, RBMXL2 is part of an anciently diverged family of RNA-binding proteins. The RBMXL2 gene evolved 65 million years ago following retro-transposition of the RBMX gene from the X chromosome to an autosome (Ehrmann et al., 2019). RBMX and RBMXL2 proteins (also known as hnRNP-G and hnRNP-GT) share 73% identity at the protein level and have the same modular structure comprising an N-terminal RNA recognition motif (RRM) and a C-terminal disordered region containing RGG repeats (Figure 1A). RBMX and RBMXL2 are also more distantly related to a gene called RBMY on the long arm of the Y chromosome that is deleted in some infertile men (with only ~37% identity between human RBMXL2 and RBMY) (Elliott et al., 1997; Ma et al., 1993). The role of RBMY in the germline is almost totally unknown, but RBMY protein has been implicated in splicing regulation (Elliott et al., 2000; Venables et al., 2000).

Figure 1 with 1 supplement see all
Download asset Open asset
RBMX primarily operates as a splicing repressor in human somatic cells.

(A) Schematic structure of RBMX family proteins (left side, cladogram) and amino acid similarity of each domain between RBMX protein and two other members of this family, RBMXL2 and RBMY. RRM, RNA recognition motif; CD, central domain important for recognition of nascent transcripts and nuclear localisation; CTD, C-terminal domain, involved in RNA binding (Elliott et al., 2019). (B) Western blot analysis shows efficient siRNA-mediated depletion of RBMX from MDA-MB-231 cells (each lane contains biologically independent replicate, apart from lane 4 which contained size markers). (C) Pie chart showing the percentages of events controlled by RBMX in both MDA-MB-231 (this study) and HEK293 (Liu et al., 2017) cells. (D) Pie chart showing the percentages of events controlled by RBMX in both MDA-MB-231 and HEK293 cells that have been previously annotated (Refseq, Ensembl, Gencode), and those that are novel to this study. (E) Bar chart showing the different types of alternative splicing events controlled by RBMX protein in both HEK293 and MDA-MB-231 cells, summarising the proportion of splicing events that are activated by RBMX versus those that are repressed. (F) Splice site score analyses for 5ʹ (left panel) and 3ʹ (right panel) splice sites repressed by RBMX compared to RBMX non-responsive alternative splice sites. eCDF, empirical Cumulative Distribution Function. Two-sample KS test two-sided p-value = 0.41 and 0.33, respectively.

Figure 1—source data 1

List of splicing defects in MDA-MB-231 and HEK293 related to Figure 1C and Figure 1—figure supplement 1A.

https://cdn.elifesciences.org/articles/89705/elife-89705-fig1-data1-v1.xlsx

The location of RBMX and RBMY on the X and Y chromosomes has important implications for their expression patterns during meiosis. The X and Y chromosomes are inactivated during meiosis within a heterochromatic structure called the XY body (Turner, 2015; Wang, 2004). Meiosis is quite a long process, and to maintain cell viability during this extended period a number of autosomal retrogenes have evolved from essential X chromosome genes. These autosomal retrogenes are actively expressed during meiosis when the X chromosome is inactive. However, it is unknown whether RBMXL2 is functionally similar enough to RBMX to provide a direct replacement during meiosis, or whether RBMXL2 has evolved differently to control meiosis-specific patterns of expression. Suggesting somewhat different activities, RBMX was recently shown to activate exon splicing inclusion, via a mechanism involving binding to RNA through its C-terminal disordered domain facilitated by recognition of m6A residues and RNA polymerase II pausing (Liu et al., 2017; Zhou et al., 2019).

Here, we have used iCLIP and RNA-seq to analyse the binding characteristics and RNA processing targets of human RBMX. We identify a novel class of RBMX-dependent ultra-long exons connected to genome stability and transcriptional control, and find that RBMX, RBMXL2, and RBMY paralogs have closely related functional activity in repressing cryptic splice site selection. Our data reveal an ancient mechanism of gene expression control by RBMX family proteins that predates the radiation of mammals, and provides a new understanding of how ultra-long exons are properly incorporated into mRNAs.

Results

RBMX primarily operates as a splicing repressor in somatic cells

We first set out to identify the spectrum of splicing events that are strongly controlled by RBMX across different human cell lines. We used RNA-seq from biological triplicate MDA-MB-231 cells treated with siRNA against RBMX (achieving >90% depletion, Figure 1B), followed by bioinformatics analysis using the SUPPA2 (Trincado et al., 2018) and MAJIQ (Vaquero-Garcia et al., 2023; Vaquero-Garcia et al., 2016) splicing prediction tools. We identified 315 changes in RNA processing patterns in response to RBMX-depletion that were of high enough amplitude to be visually confirmed on the IGV genome browser (Robinson et al., 2011; Figure 1—figure supplement 1A; Figure 1—source data 1). Analysis of these splicing events within existing RNA-seq data from HEK293 cells depleted for RBMX (GSE74085) (Liu et al., 2017) revealed 148 high amplitude events that are controlled by RBMX in both HEK293 and MDA-MB-231 cells (Figure 1C). We concentrated our downstream analysis on these splicing events (Figure 1—source data 1). 92% of the splicing events regulated by RBMX in human somatic cells were already annotated on Ensembl, Gencode or Refseq (Figure 1D). Strikingly two-thirds of these events are repressed by RBMX, meaning they were increasingly used in RBMX-depleted cells compared to control, and include exon inclusion, alternative 5ʹ and 3ʹ splice sites, exitrons, and intron retention (Figure 1E). Furthermore, analysis of splice site strength revealed that, unlike splice sites activated by RBMX (Figure 1—figure supplement 1B), alternative splice sites repressed by RBMX have comparable strength to more commonly used splice sites (Figure 1F). This means that RBMX operates as a splicing repressor in human somatic cells to prevent the use of ‘decoy’ splice sites that could disrupt normal patterns of gene expression.

Splicing control and sites of RBMX protein-RNA interaction are enriched within long internal exons

The above data indicated that RBMX has a major role in repressing cryptic splicing patterns in human somatic cells. To further correlate splicing regulation to patterns of RBMX protein-RNA interactions, we next mapped the distribution of RBMX-RNA binding sites in human somatic cells. We engineered a stable human HEK293 cell line to express RBMX-FLAG fusion protein in response to tetracycline addition. Western blotting showed that expression of RBMX-FLAG was efficiently induced after tetracycline treatment. Importantly, levels of the induced RBMX-FLAG protein were similar to those of endogenous RBMX (Figure 2A). We next used this inducible cell line to carry out individual nucleotide resolution crosslinking and immunoprecipitation (iCLIP) – a technique that produces a global picture of protein-RNA binding sites (Konig et al., 2011). After crosslinking, RBMX-FLAG protein was immunoprecipitated, then infra-red labeled RNA-protein adducts were isolated (Figure 2B) and subjected to library preparation. Following deep sequencing of biological triplicate experiments, 5–10 million unique reads (referred to here as iCLIP tags, representing sites of RBMX protein-RNA cross-linking) were aligned to the human genome. Each individual iCLIP replicate showed at least 70% correlation with each of the others (Figure 2—figure supplement 1A). K-mer motif analysis revealed RBMX preferentially binds to AG-rich sequences (Figure 2C and Figure 2—figure supplement 1B).

Figure 2 with 1 supplement see all
Download asset Open asset
Splicing control and sites of RBMX protein-RNA interaction are enriched within long internal exons.

(A) Western blot showing levels of RBMX-FLAG protein, expressed after 24 hr treatment with tetracycline, compared to endogenous RBMX within HEK293 cells, both detected using α-RBMX antibody. α-GAPDH antibody was used as a loading control. Each lane corresponds to a biologically independent replicate sample. (B) RNAs cross-linked to RBMX-FLAG during individual nucleotide resolution crosslinking and immunoprecipitation (iCLIP) were detected through the infrared adaptor (RBMX-RNA complexes). Lane 1, anti-FLAG pull-down from crosslinked HEK293 control cells not expressing RBMX-FLAG proteins, treated with 0.8 U/ml RNaseI. Lane 3, RBMX-FLAG pull-down crosslinked to RNA, treated with 2.5 U/ml RNaseI. Lanes 5–7, RBMX-FLAG pull-down crosslinked to RNA, treated with 0.8 U/ml RNaseI. Samples in lanes 5–7 were used for iCLIP library preparation. Lanes 2 and 4 are empty. (C) K-mer analysis shows the top 10 enriched motifs within sequences surrounding RBMX iCLIP tags. (D) Boxplot analysis shows sizes of exons containing splicing events regulated by RBMX, grouped by whether they contain CLIP tags or not. ****, p<0.0001 (Mann-Whitney test). (E) Boxplot analysis shows the distribution of exon sizes relative to: all or internal exons contained in mRNA genes expressed in HEK293 cells (Liu et al., 2017); exons regulated by RBMX as identified by RNA-seq; exons containing RBMX binding sites as identified by iCLIP, listed independently of iCLIP tag density. Median sizes for each group are shown. ****, p<0.0001 (Wilcoxon rank test and Kruskal-Wallis test). (F) Distribution plot of exon sizes for the groups shown in (E). Note the increased accumulation of exons larger than 1000 bp (ultra-long exons) in RBMX-bound and regulated exons compared to all exons expressed in HEK293 (Liu et al., 2017). (G) Bar plot indicating the proportion of ultra-long exons in the groups shown in (E, F). ****, p<0.0001 (Chi-squared test). (H) Histogram of hexamer Z-scores for ultra-long exons (exceeding 1000 nt) versus non-ultra-long exons from Ensembl canonical mRNA transcripts. The top five enriched hexamers are shown with corresponding Z-scores. Grey dots indicate histogram bins containing one of the top 25 RBMX iCLIP hexamer motifs. (I) Similar analysis as in (H), but for ultra-long exons with evidence of RBMX binding or regulation versus RBMX-independent ultra-long exons.

Figure 2—source data 1

List of splicing defects with nearby RBMX CLIP tags from HEK293 cells related to Figure 2D and Figure 2—figure supplement 1C.

https://cdn.elifesciences.org/articles/89705/elife-89705-fig2-data1-v1.xlsx
Figure 2—source data 2

List of exons analysed in Figure 2E–G.

https://cdn.elifesciences.org/articles/89705/elife-89705-fig2-data2-v1.txt

In line with previous work on other RNA binding proteins (Van Nostrand et al., 2020), only 31% of the RNA splicing events that are controlled by RBMX in both HEK293 cells and MDA-MB-231 cells were identified by iCLIP as direct targets for RBMX binding (Figure 2—figure supplement 1C, and Figure 2—source data 1). Furthermore, when we plotted the fraction of RBMX iCLIP tags present near exons that contain splicing defects in the absence of RBMX, and compared it to iCLIP tags present near a set of exons unaffected by RBMX depletion, we did not detect significant enrichment of RBMX binding within exons that contain splice sites repressed by RBMX (Figure 2—figure supplement 1D, E). There was significant enrichment of RBMX binding seen in flanking introns (downstream for RBMX-repressed and upstream for RBMX-activated). However, RBMX-responsive internal exons that did contain RBMX iCLIP tags were significantly longer than the ones that are not bound by RBMX (Figure 2D and Figure 2—source data 1). We therefore compared the length of the internal exons regulated (identified by RNA-seq) and bound by RBMX (identified by iCLIP) within protein-coding genes to all internal mRNA exons expressed in HEK293 (Liu et al., 2017). We reasoned that larger exons might have a higher chance to be bound by RBMX merely because of their large size. To minimise this effect, we did not take into account the density of RBMX binding and instead considered all exons that contained at least one iCLIP tag. Strikingly, we found that exons regulated and bound by RBMX were significantly longer than the median size of HEK293 mRNA exons which is ~130 bp (Figure 2E, and Figure 2—source data 2). This led us to test whether RBMX protein is preferentially associated with long exons. For this, we plotted the distribution of internal exons bound and regulated by RBMX together with all internal exons expressed from HEK293 mRNA genes (Liu et al., 2017). We found that RBMX controls and binds two different classes of exons: the first has a comparable length to the average HEK293 exon, while the second is extremely long, exceeding 1000 bp in length (Figure 2F). We defined this second class as ‘ultra-long exons,’ which represented the 17.6% of internal exons regulated by RBMX and 18.9% of the ones that contained RBMX iCLIP tags. These proportions were significantly enriched compared to the general abundance of internal ultra-long exons expressed from HEK293 cells, which was only 0.4% (Figure 2G). K-mer analyses also showed that while ultra-long exons within mRNAs are rich in AT-rich sequences compared to shorter exons (Figure 2H), the ultra-long exons that are either regulated or bound by RBMX displayed enrichment of AG-rich sequences (Figure 2I), consistent with our identified RBMX-recognised sequences (Figure 2C). Overall, this data revealed a function for RBMX in the regulation of splicing of a particular group of ultra-long exons.

RBMX is important for proper splicing inclusion of full-length ultra-long exons within genes involved in processes including DNA repair and chromosome biology

We next wondered whether ultra-long exons regulated by RBMX (which represented 11.6% of all ultra-long internal exons from genes expressed in HEK293) had any particular feature compared to ultra-long exons that were RBMX-independent. To determine whether RBMX regulates particular classes of genes we performed Gene ontology analysis. Both the genes bound by RBMX (detected using iCLIP, Figure 3—figure supplement 1A and Figure 3—source data 1) and regulated by RBMX in both MDA-MB-231 and HEK293 cell lines (detected using RNA-seq, Figure 3—figure supplement 1B and Figure 3—source data 1) each showed individual global enrichment in functions connected to genome stability and gene expression. Similarly, Gene ontology analyses for genes that contained ultra-long exons bound by and dependent on RBMX for correct splicing were enriched in pathways involving cell cycle, DNA repair, and chromosome regulation, compared to all expressed genes with ultra-long exons (Figure 3A and Figure 3—source data 1). These data are consistent with published observations (Adamson et al., 2012; Munschauer et al., 2018; Zheng et al., 2020) that depletion of RBMX reduces genome stability. In addition, comet assays also detected increased levels of genome instability after RBMX depletion (Figure 3—figure supplement 1C, D).

Figure 3 with 2 supplements see all
Download asset Open asset
RBMX protein is important for full-length splicing inclusion of ultra-long exons involved in DNA repair and chromosome biology.

(A) Gene ontology analysis of genes with ultra-long exons regulated and bound by RBMX displaying significant gene ontology biological process (GOBP) terms containing at least 5% of the total gene list. FDR, False Discovery Rate. Count, number of genes in the GOBP group. GeneRatio, proportion of genes in the GOBP group relative to the full list of RBMX-regulated genes. (B) Snapshot of RNA-seq merged tracks from MDA-MB-231 cells and RBMX iCLIP tags from HEK293 cells from the IGV genome browser shows cryptic 3ʹ splice sites repressed by RBMX in ETAA1 exon 5. At the bottom, the schematic of PCR products identified by RT-PCR in (C). (C) RT-PCR analysis shows splicing inclusion of ETAA1 exon 5 upon siRNA-mediated depletion of RBMX in the indicated cell lines (separate lanes correspond to analysis of independent biological replicate samples). (D) Western blot analysis shows that ETAA1 protein expression is dependent on RBMX. Anti-Tubulin detection was used as loading control (separate lanes correspond to independent biological replicate samples). (E) Snapshot of RNA-seq merged tracks from MDA-MB-231 cells and RBMX iCLIP tags from HEK293 cells from the IGV genome browser shows RBMX represses a cryptic 3ʹ splice site within the ultra-long exon 13 of REV3L. At the bottom, the schematic of PCR products identified by RT-PCR in (F). (F) RT-PCR analysis shows splicing inclusion of REV3L exon 13 upon siRNA-mediated depletion of RBMX in the indicated cell lines (separate lanes correspond to the analysis of independent biological replicate samples). (G) Snapshot of RNA-seq merged tracks from MDA-MB-231 cells and RBMX iCLIP tags from HEK293 cells from IGV genome browser. The location of experimentally mapped branchpoints relative to RBMX binding is indicated.

Figure 3—source data 1

Gene ontology analyses related to Figure 3A and Figure 3—figure supplement 1A, B.

https://cdn.elifesciences.org/articles/89705/elife-89705-fig3-data1-v1.xlsx

The above data indicated that RBMX-RNA binding interactions and splicing control by RBMX are particularly associated with long internal exons and enriched within classes of genes involved in genome stability. These exons included the 2.1 Kb exon 5 of the ETAA1 (Ewings Tumour Associated Antigen 1) gene, where RBMX potently represses a cryptic 3ʹ splice site that reduces the size of this exon from 2.1 Kb to 100 bp (Figure 3B and Figure 3—figure supplement 2A). RT-PCR analysis confirmed that RBMX depletion causes a much shorter version of ETAA1 exon 5 to prevail, particularly in MDA-MB-231 and NCI-H520 cells, but less in MCF7 cells (Figure 3C). ETAA1 encodes a replication stress protein that accumulates at sites of DNA damage and is a component of the ATR signalling response (Bass et al., 2016). Selection of RBMX-repressed cryptic 3ʹ splice sites within ETAA1 exon 5 removes a long portion of the open reading frame (Figure 3—figure supplement 2B). Consistent with the penetrance of this ETAA1 splicing defect being sufficiently high to affect protein production, no ETAA1 protein was detectable 72 hr after RBMX depletion from MDA-MB-231 cells (Figure 3D).

Another ultra-long exon is found within the REV3L gene that encodes the catalytic subunit of DNA polymerase ζ that functions in translesion DNA synthesis (Martin and Wood, 2019). RBMX similarly represses a cryptic 3ʹ splice site within the ultra-long exon 13 of the REV3L gene (~4.2 Kb), that has an extremely high density of RBMX binding (Figure 3E). RT-PCR analysis confirmed a strong splicing switch to a cryptic splice site within REV3L exon 13 after RBMX was depleted from MDA-MB-231, MCF7, and NCI-H520 cells (Figure 3F).

We also detected extremely high-density RBMX protein binding within exon 9 of the ATRX gene (3 Kb in length) that encodes a chromatin remodelling protein involved in mitosis. Depletion of RBMX results in the expression of a shortened version of ATRX exon 9, caused by the formation of an exitron through the selection of cryptic 5ʹ and 3ʹ splice sites within exon 9 (Figure 3—figure supplement 2C).

RBMX protein-RNA interactions may insulate important splicing signals from the spliceosome

The iCLIP data suggested a model where RBMX protein binding may insulate ultra-long exons so that cryptic splice sites cannot be accessed by the spliceosome. This model predicted that RBMX binding sites would be close to important sequences used for the selection of cryptic splice sites. RBMX iCLIP tags mapped just upstream of the cryptic 3ʹ splice sites within ETAA1 exon 5 in HEK293 cells and MDA-MB-231 cells after RBMX depletion (Figure 3B), suggesting that RBMX may bind close to the branchpoints used to generate these cryptic splicing patterns. However, although usually located close to their associated 3ʹ splice sites, in some cases branchpoints can be located far upstream (Gooding et al., 2006). We tested the prediction that RBMX may sterically interfere with components of the spliceosome by directly mapping the branchpoints associated with the use of these cryptic ETAA1 splice sites. To facilitate mapping of the branchpoint sequences used by the cryptic 3ʹ splice site within ETAA1 exon 5, we made a minigene by cloning the ultra-long ETAA1 exon 5 and flanking intron sequences between constitutively spliced β-globin exons (Figure 3—figure supplement 2D). Confirming that this minigene recapitulated cryptic splicing patterns, after transfection into HEK293 cells we could detect splicing inclusion of both the full-length and shorter (cryptic) versions of ETAA1 exon 5 mRNA isoforms using multiplex RT-PCR (Figure 3—figure supplement 2E). We then used an RT-PCR assay (Figure 3—figure supplement 2F) to monitor the position of branchpoint just upstream of the cryptic 3ʹ splice sites of ETAA1 exon 5 (Královičová et al., 2021). Sanger sequencing of the amplification product made in this assay confirmed that the branchpoint sequences used by these cryptic 3ʹ splice sites are adjacent to RBMX binding sites (Figure 3G and Figure 3—figure supplement 2G).

RBMXL2 and RBMY can replace the activity of RBMX in somatic cells

The above data showed that although RBMX can activate the splicing of some exons, it predominantly operates as a splicing repressor in human somatic cells, and moreover has a key role in repressing cryptic splicing within ultra-long exons. This pattern of RBMX activity is thus very similar to that previously reported for RBMXL2 in the germline, where RBMXL2 represses cryptic splice sites during meiosis. RBMXL2 is expressed during male meiosis when the X chromosome is silenced. To directly mimic this switch in protein expression we constructed a HEK293 RBMXL2-FLAG tetracycline-inducible cell line, from which we depleted RBMX using siRNA (Figure 4A). Western blots showed that RBMX was successfully depleted after siRNA treatment, and the RBMXL2-FLAG protein was strongly expressed after tetracycline induction, thus simulating their relative expression patterns in meiotic cells (Figure 4B). We globally investigated patterns of splicing in these rescue experiments by performing RNA-seq analysis of each of the experimental groups. Strikingly, almost 80% of splicing defects that we could detect after RBMX-depletion were rescued by tetracycline-induced RBMXL2 (Figure 4C, and Figure 4—source data 1). Exons rescued by RBMXL2 tended to be larger than exons not restored (Figure 4D), and most of the splice events that were restored by RBMXL2 expression had nearby RBMX binding sites evidenced by iCLIP (Figure 4E). We then validated three cryptic splicing patterns by RT-PCR. Confirming our previous finding, in the absence of tetracycline treatment depletion of RBMX led to an increased selection of cryptic splice sites within ETAA1 exon 5 and REV3L exon 13, and to the formation of an exitron within ATRX exon 9 (Figure 4F–K, compare lanes 1–3 with lanes 4–6). Consistent with our RNA-seq analysis (Figure 4—figure supplement 1A–C), tetracycline-induction of RBMXL2 was sufficient to repress production of each of these aberrant splice isoforms (Figure 4F–K, compare lanes 7–9 with lanes 10–12). These experiments indicate that RBMXL2 is able to replace RBMX activity in regulating ultra-long exons within somatic cells.

Figure 4 with 2 supplements see all
Download asset Open asset
RBMXL2 can replace the activity of RBMX in ensuring proper splicing inclusion of ultra-long exons.

(A) Schematic of the time-course experiment used to analyse human RBMXL2 function in RBMX-depleted HEK293 cells. All conditions were repeated in biological triplicates. (B) Western blot analysis shows that RBMXL2-FLAG protein is stably expressed in HEK293 cells after 24 hr of tetracycline induction, and RBMX protein is successfully depleted after 72 hr of siRNA treatment. Separate lanes correspond to independent biological replicate samples. (C) Pie chart showing the percentage of splicing events detected by RNA-seq that were defective in RBMX-depleted cells and restored by overexpression of RBMXL2. (D) Boxplot analysis shows the distribution of exon sizes relative to exons undergoing defective splicing in RBMX-depleted cells, grouped by whether splicing patters were restored by RBMXL2 overexpression. **p<0.01 (Mann-Whitney test). (E) Bar plot analysis shows the proportion of exons containing RBMX individual nucleotide resolution crosslinking and immunoprecipitation (iCLIP) tags, grouped by whether splicing patterns were restored by RBMXL2 overexpression. ****p<0.0001 (Chi-squared test). (F, H, J) Capillary gel electrophoretograms show RNA processing patterns of endogenous ultra-long exons within ETAA1, REV3L, and ATRX controlled by RBMX and RBMXL2 analysed using isoform-specific RT-PCR. Separate lanes correspond to the analysis of independent biological replicate samples. (G, I, K) Bar charts showing percentage splicing inclusion (PSI) of cryptic isoforms from the endogenous ETAA1, REV3L, and ATRX genes under the different experimental conditions, measured in experiments in (F), (H) and (J), respectively. p-values were calculated using an unpaired t-test. * p< 0.05; ***p< 0.001; ****p<0.0001, using n=3 biological replicates for each condition as shown in capillary gel electrophoretograms.

Figure 4—source data 1

List of splicing defects restored by overexpression of RBMXL2 related to Figure 4C.

https://cdn.elifesciences.org/articles/89705/elife-89705-fig4-data1-v1.xlsx

RBMX and RBMXL2 are both more distantly related to the Y chromosome-encoded RBMY protein, with RBMX and RBMY diverging when the mammalian Y chromosome evolved (Figure 1A). RBMY has also been implicated in splicing control (Nasim et al., 2003; Venables et al., 2000), but its functions are very poorly understood. We thus tested whether RBMY might also be performing a similar function to RBMX. Employing a HEK293 cell line containing tetracycline-inducible, FLAG-tagged RBMY protein, we detected successful recovery of normal splicing patterns of the ultra-long exons within the ETAA1, REV3L, and ATRX genes within RBMX-depleted cells 24 hr after tetracycline induction of RBMY (Figure 4—figure supplement 2). These results indicate that even despite its more extensive divergence, RBMY can also functionally replace RBMX in cryptic splice site control within long exons. Thus, splicing control mechanisms by RBMX family proteins pre-date the evolution of the mammalian X and Y chromosomes.

The disordered domain of RBMXL2 is required for efficient splicing control of ultra-long exons

The above data showed that RBMX predominantly operates as a splicing repressor in somatic cells, thus performing a functionally parallel role to RBMXL2 in the germline. Although RBMX contains an RRM domain that is the most highly conserved region compared with RBMXL2 and RBMY, splicing activation by RBMX depends on its C-terminal disordered domain that also binds to RNA (Liu et al., 2017; Moursy et al., 2014). We thus reasoned that if RBMX and RBMXL2 were performing equivalent molecular functions, the rescue of splicing by RBMXL2 should be mediated by the disordered region of RBMXL2 alone, independent of the RRM (Liu et al., 2017; Moursy et al., 2014). To test this prediction, we created a new tetracycline-inducible HEK293 cell line expressing the disordered region of the RBMXL2 protein and not the RRM domain (RBMXL2ΔRRM, Figure 5A). Tetracycline induction of this RBMXL2ΔRRM protein was able to rescue siRNA-mediated depletion of RBMX (Figure 5B–G), directly confirming that the C-terminal disordered domain of RBMXL2 protein is responsible for mediating cryptic splicing repression.

Figure 5
Download asset Open asset
The disordered domain of RBMXL2 is required to mediate splicing control of ultra-long exons in HEK293 cells.

(A) Western blot analysis shows that RBMXL2ΔRRM-FLAG protein is stably expressed in HEK293 cells after 24 hr of tetracycline induction, and RBMX protein is successfully depleted after 72 hr of siRNA treatment. Separate lanes correspond to the analysis of independent biological replicate samples. (B, D, F) Capillary gel electrophoretograms show RNA processing patterns of endogenous ultra-long exons within ETAA1, REV3L, and ATRX analysed using isoform-specific RT-PCR. Separate lanes correspond to the analysis of independent biological replicate samples. (C, E, G) Bar charts showing percentage splicing inclusion (PSI) of cryptic isoforms from the endogenous ETAA1, REV3L, and ATRX genes under the different experimental conditions, measured in experiments in (B), (D), and (F), respectively. p-values were calculated using an unpaired t-test. ****p<0.0001, using biologically independent sampleas.

Discussion

We previously showed that the germ cell-specific RBMXL2 protein represses cryptic splice site selection during meiotic prophase. Here, we find that this is part of a bigger picture, where the closely related but more ubiquitously expressed RBMX protein also provides a similar activity within somatic cells. Supporting this conclusion, both RBMX and RBMXL2 proteins most frequently operate as splicing repressors in their respective cell types. We further find that RBMX binds and is key for proper splicing inclusion of a group of ultra-long exons, defined as exceeding 1 Kb in length. RBMXL2 similarly represses cryptic splice sites within ultra-long exons of genes involved in genome stability including Brca2 and Meioc (Ehrmann et al., 2019). Furthermore, RBMXL2 and even the more diverged RBMY protein are able to provide a direct replacement for RBMX splicing control within human somatic cells. Although many of the splice sites within ultra-long exons we find to be repressed by RBMX are already annotated, they are not usually selected in the human cell lines we investigated and thus represent potential decoy splice sites that would interfere with full-length gene expression.

Long human exons provide an enigma in understanding gene expression. Most human exons have evolved to be quite short (~130 bp) to facilitate a process called exon definition, in which protein-protein interactions between early spliceosome components bound to closely juxtaposed splice sites promote full spliceosome assembly (Black, 1995; Robberson et al., 1990). Exon definition also requires additional RNA binding proteins to recognise exons and flanking intron sequences. These include members of the SR protein family that bind to exonic splicing enhancers (ESEs) and activate exon inclusion, with exons typically having higher ESE content relative to introns. While the mechanisms that ensure proper splicing inclusion of long exons are not well understood, cryptic splice sites would be statistically more likely to occur within long exons compared to short exons, where they could prevent full-length exon inclusion. Cryptic splice sites within long exons could be particularly problematic (compared to an intronic location) since they would be embedded within a high ESE sequence environment. For example, some long exons require interactions with the SR protein SRSF3 and hnRNP K and phase separation of transcription factors to be spliced (Kawachi et al., 2021). Hence, although the functions of hnRNPs in repressing cryptic splice events have often concentrated on their role within introns, other hnRNPs as well as RBMX might also show enriched binding within ultra-long exons to help repress cryptic splice site selection.

The X chromosome is required for viability. This means that meiotic sex chromosome inactivation (inactivation of the X and Y chromosomes during meiosis) coordinately represses a panel of essential genes on the X chromosome, thus opening the need for alternative routes to fulfil their function (Turner, 2015). A number of essential X-linked genes have generated autosomal retrogenes that are expressed during meiosis, although genetic inactivation of some of these retrogenes causes a phenotype that manifests outside of meiosis (Wang, 2004). An exception is exemplified by the RPL10 and RPL10L proteins that are 95% identical: RPL10 mutation causes meiotic arrest, and RPL10L has been shown to directly replace its X-linked ortholog RPL10 during meiosis (Jiang et al., 2017; Wang, 2004). RBMXL2 is the only other X-linked retrogene that has been shown to be essential for meiotic prophase (Ehrmann et al., 2019). Here, we show that ectopic expression of RBMXL2 can compensate for the lack of RBMX in somatic cells. This is consistent with a recent model suggesting that RBMXL2 directly replaces RBMX function during meiosis because of transcriptional inactivation of the X chromosome (Aldalaqan et al., 2022). This general requirement for functionally similar RBMX family proteins across somatic and germ cells further suggests that RBMX-family functions in splicing control have been required for ~200 million years, since before the divergence of separate RBMX and RBMY genes early in mammalian evolution.

The iCLIP data reported here show a high density of RBMX binding within ultra-long exons, consistent with a model in which RBMX protein binds to RNA mask sequences required for cryptic splice site selection. Such RBMX binding would block access to spliceosome components or splicing activator proteins (Figure 6). Our data show that the C-terminal disordered domain of RBMXL2 protein is sufficient to control splicing inclusion of ultra-long exons. This is exactly analogous to the mechanism of control of splicing activation by RBMX, which occurs via recognition of m6A-modified RNA targets via the C-terminal disordered domain (Liu et al., 2017). Intriguingly, global studies have shown that m6A residues are enriched within some long internal exons (Dominissini et al., 2012), where they might help facilitate RBMX protein-RNA interactions. The C-terminal disordered region of RBMX is also reported to mediate protein-protein interactions, therefore, shorter exons that show defective splicing in RBMX-depleted cells but are not directly bound by RBMX could rely on different regulatory mechanisms. RBMY, RBMX and RBMXL2 directly interact with the SR protein Tra2β (Elliott et al., 2000; Venables et al., 2000) and have opposing functions during RNA binding and splicing regulation (Nasim et al., 2003; Venables et al., 2000). Hence, it is still possible that RBMX family proteins counteract recognition by SR proteins of ESEs near cryptic splice sites via a protein-protein interaction mechanism.

Figure 6
Download asset Open asset
Model of cryptic splice site repression within ultra-long exons by RBMX family proteins.

Ultra-long exons may be intrinsically fragile as they could contain cryptic splice sites within an environment rich in exonic splicing enhancers (ESEs). RBMX protein binding within ultra-long exons may directly block access of spliceosome components to cryptic splice sites, and depletion of RBMX from somatic cells activates the selection of cryptic splice sites. This means a shorter version of the originally ultra-long exon is included, that fits more easily with exon definition rules normally followed for median-size exons. During meiosis, the lack of RBMX caused by X chromosome inactivation is compensated by the expression of RBMXL2 protein.

Extensive literature shows that RBMX is important for genome stability, including being involved in replication fork activity (Munschauer et al., 2018; Zheng et al., 2020), sensitivity to genotoxic drugs (Adamson et al., 2012) and cell proliferation (https://orcs.thebiogrid.org/Gene/27316). Interestingly, many of the ultra-long exons controlled by RBMX are within genes important for genome stability, including REV3L, ATRX, and ETAA1. This makes it likely that RBMX contributes to maintaining genome stability by ensuring full-length protein expression of genes important in this process. As an example, we show here that depletion of RBMX protein causes aberrant selection of a high amplitude cryptic splice site within ETAA1 exon 5 which prevents detectable expression of ETAA1 protein, and contributes to genome instability (Bass et al., 2016). Cancer and neurological disorders are amongst the most common human diseases associated with defective DNA damage response (Jackson and Bartek, 2009). The double role of RBMX in genome maintenance via both direct participation in the DNA damage response and splicing regulation of genome stability genes could explain why mutations of RBMX are associated with an intellectual disability syndrome (Cai et al., 2021; Shashi et al., 2015), and why RBMX has been identified as a potential tumour suppressor (Adamson et al., 2012; Elliott et al., 2019). The data reported in this paper thus have implications for understanding the links between RNA processing of unusual exons, genome stability, and intellectual disability.

Materials and methods

Key resources table
Reagent type (species) or resourceDesignationSource or referenceIdentifiersAdditional information
Gene (Homo sapiens)RBMXGenBankNCBI Gene: 27316 Ensembl: ENSG00000147274
Gene (Homo sapiens)RBMXL2GenBankNCBI Gene: 27288 Ensembl: ENSG00000170748
Gene (Homo sapiens)RBMY/ RBMY1A1GenBankNCBI Gene: 5940 Ensembl: ENSG00000234414
Gene (Homo sapiens)ETAA1GenBankNCBI Gene: 54465 Ensembl: ENSG00000143971
Gene (Homo sapiens)REV3LGenBankNCBI Gene: 5980 Ensembl: ENSG00000009413
Gene (Homo sapiens)ATRXGenBankNCBI Gene: 546 Ensembl: ENSG00000085224
Cell line (Homo sapiens)MDA-MB-231ATCCHTB-26
Cell line (Homo sapiens)MCF7ATCCHTB-22
Cell line (Homo sapiens)U-2 OSATCCHTB-96
Cell line (Homo sapiens)NCI-H520ATCCHTB-182
Cell line (Homo sapiens)Flp-In–293
Flp-In. T-REx.-293 Cell Line		ThermofisherR78007Used to make stable over-expressing cells.
Cell line (Homo sapiens)Flp-In–293 FLAG-RBMXThis studyUsed to express tagged RBMX protein in human cells. Available from Elliott lab.
Cell line (Homo sapiens)Flp-In–293 FLAG-RBMXL2This studyUsed to express tagged RBMXL2 protein in human cells. Available from Elliott lab.
Cell line (Homo sapiens)Flp-In–293 FLAG-RBMYThis studyUsed to express tagged RBMY protein in human cells. Available from Elliott lab.
Cell line (Homo sapiens)Flp-In–293 FLAG- RBMXL2ΔRRMThis studyUsed to express tagged RBMX protein without the RRM in human cells. Available from Elliott lab.
Chemical compoundTetracyclineSigma-AldrichT7660
Recombinant DNA reagentpOG44 (plasmid)Thermofisher
Scientific		Expresses Flp recombinase.
Recombinant DNA reagentFLAG-pcDNA5 (plasmid)Thermofisher
Scientific		Expression of constructs in the stable Cell lines was induced by treatment with 1 µg/ml tetracycline for 24 hr.
Recombinant DNA reagentpXJ41 (miniGene plasmid)Bourgeois et al., 1999
Sequence-based reagentsiRNAsIDThs.Ri.RBMX.13.1, hs.Ri.RBMX.13.2
Antibodyanti-FLAG mouse monoclonal antibodySigma-AldrichCat# F1804
RRID:AB_262044		CLIP (5 μg), WB (1:2000)
AntibodyNormal mouse IgG (mouse antibody)Santa Cruz BiotechnologyCat# sc-2025
RRID:AB_737182		CLIP: 5 μg
AntibodyAnti-RBMX (rabbit polyclonal antibody)Cell Signalling TechnologyCat# D7C2V
RRID:AB_2798614		WB (1:1000)
AntibodyAnti-ETAA1 (rabbit polyclonal antibody)Sigma-AldrichCat# HPA035048
RRID:AB_10670300		WB (1:1000)
AntibodyAnti-alpha tubulin (rabbit polyclonal antibody)AbcamCat# ab18251
RRID:AB_2210057		WB (1:2000)
AntibodyAnti-GAPDH (mouse monoclonal antibody)AbceptaCat# P04406WB (1:2000)
Commercial assay or kitRNeasy Plus Mini KitQiagenCat#74134
Commercial assay or kitComet Assay KitAbcamab238544
Software, algorithmFastqchttps://anaconda.org/ See: Andrews, 2010
Software, algorithmSTARhttps://anaconda.org/v.2.4.2See: Dobin et al., 2013
Software, algorithmSalmonhttps://anaconda.org/v.0.9.1See: Patro et al., 2017
Software, algorithmHisat2https://anaconda.org/v.2.2.1See: Kim et al., 2015
Software, algorithmSamtoolshttps://anaconda.org/v.1.14See: Li et al., 2009
Software, algorithmMAJIQhttps://anaconda.org/See Vaquero-Garcia et al., 2016
Software, algorithmSUPPA2https://anaconda.org/See: Trincado et al., 2018
Software, algorithmiCLIPlibGithub,
https://github.com/sudlab/iCLIPlib,
copy archived at Sudbery et al., 2022.
Software, algorithmiMAPShttps://imaps.goodwright.com/
Software, algorithmR/RStudioCranv.3.5.1
Software, algorithmDESeq2https://bioconductor.org/v.1.16.1See: Love et al., 2014
Software, algorithmbiomaRthttps://bioconductor.org/v.2.52.0See: Durinck et al., 2005
Software, algorithmclusterProfiler::enrichGOhttps://bioconductor.org/v.4.4.4See: Yu et al., 2012
Software, algorithmRevigohttps://bioconductor.org/See: Supek et al., 2011
Software, algorithmggplot2https://bioconductor.org/v.3.3.6See: Wickham, 2016
Software, algorithmChIPseekerhttps://bioconductor.org/v.1.32.0See: Yu et al., 2015
Software, algorithmPseudorankhttps://bioconductor.org/v.1.0.1See: Happ et al., 2020
Software, algorithmIntegrative Genomics Viewerhttps://igv.org/See: Robinson et al., 2011
Software, algorithmGraphPad Prismhttps://www.graphpad.comv.9.5.0
Software, algorithmMedCalchttps://medcalc.org/20.218

Cell culture and cell lines

Request a detailed protocol

MDA-MB-231 (ATCC HTB-26), MCF7 (ATCC HTB-22), U-2 OS (ATCC HTB-96), and NCI-H520 (ATCC HTB-182) cells were maintained in Dulbecco′s Modified Eagle′s Medium (DMEM) high glucose pyruvate medium (Gibco, #10569010), supplemented with 10% fetal bovine serum (FBS, Gibco, #21875034), and 1% Penicillin-Streptomycin (Gibco, #15140130). HEK293 (ATCC CRL-1573) were maintained in DMEM plus 10% fetal bovine serum. Cell line validation was carried out using STR profiling according to the ATCC guidelines. All cell lines underwent regular mycoplasma testing.

Generation of tetracycline-inducible cell lines

Request a detailed protocol

RMBX, RBMXL2, RBMY, and RBMXL2ΔRRM genes were cloned onto a FLAG-pcDNA5 vector and co-transfected with pOG44 plasmid into Flp-In T-REX HEK293 cells as previously described (Ehrmann et al., 2016). RBMX-FLAG, RBMXL2-FLAG, RBMY-FLAG, and RBMXL2ΔRRM-FLAG expression was induced by the addition of 1 µg/ml tetracycline (Sigma-Aldrich) to promote expression via a tetracycline-inducible promoter. The Flp-In HEK293 cells were cultured in high glucose pyruvate medium (Gibco, #10569010), supplemented with 10% FBS (Gibco, #21875034), and 1% Penicillin-Streptomycin (Gibco, #15140130).

siRNA knockdown and tetracycline induction

Request a detailed protocol

RBMX transient knockdown was established using two different pre-designed siRNAs targeting RBMX mRNA transcripts (hs.Ri.RBMX.13.1 and hs.Ri.RBMX.13.2, from Integrated DNA Technologies). Negative control cells were transfected with control siRNA (Integrated DNA Technologies, # 51-01-14-04). Cells were seeded onto six-well plates forward transfected with Lipofectamine RNAiMAX transfection reagent (Invitrogen, # 13778150) according to manufacturer′s instructions using 30 pmol of siRNA for 72 hr at 37 °C before harvesting. For tetracycline-inducible cell lines, Flp-In HEK293 cells expressing either RBMXL2-FLAG, or RBMY-FLAG, or RBMXL2ΔRRM-FLAG genes were similarly seeded onto six-well plates and treated with RBMX and control siRNAs for 72 hr at 37 °C. 24 hr before harvesting 1 µg/ml of tetracycline (Sigma-Aldrich) was added to half of the siRNA-treated samples to promote the expression of FLAG-tagged proteins.

RNA-seq

Request a detailed protocol

RNA was extracted from cells using RNeasy Plus Mini Kit (Qiagen #74134) following the manufacturer’s instructions and re-suspended in nuclease-free water. RNA samples were DNase treated (Invitrogen, AM1906). For siRNA-treated MDA-MB-231 cells, paired-end sequencing was done initially for two samples, one of negative control and one of RBMX knock-down, using an Illumina NextSeq 500 instrument. Adapters were trimmed using trimmomatic v.0.32. Three additional biological repeats of negative control and RBMX siRNA-treated MDA-MB-231 cells were then sequenced using an Illumina HiSeq 2000 instrument. The base quality of raw sequencing reads was checked with FastQC (Andrews, 2010). RNA-seq reads were mapped to the human genome assembly GRCh38/hg38 using STAR v.2.4.2 (Dobin et al., 2013) and subsequently quantified with Salmon v.0.9.1 (Patro et al., 2017) and DESeq2 v.1.16.1 (Love et al., 2014) on R v.3.5.1. All snapshots indicate merged tracks produced using samtools (Li et al., 2009) and visualised with IGV (Robinson et al., 2011). For HEK293 cells treated with either RBMX or control siRNA, either in the absence or in the presence of tetracycline, RNAs were sequenced using an Illumina NextSeq 500 instrument. Quality of the reads was checked with FastQC (Andrews, 2010). Reads were then aligned to the human genome assembly GRCh38/hg38 to produce BAM files using hisat2 v.2.2.1 (Kim et al., 2015) and samtools v.1.14 (Li et al., 2009) and visualised using IGV (Robinson et al., 2011).

Identification of splicing changes

Request a detailed protocol

Initial comparison of single individual RNA-seq samples from RBMX-depleted and control cells was carried out using MAJIQ (Vaquero-Garcia et al., 2016), which identified 596 unique local splicing variations (LSV) at a 20% dPSI minimum cut off from 505 different genes potentially regulated by RBMX. These LSVs were then manually inspected using the RNA-seq data from the second RNA sequencing of biological replicates for both RBMX-depleted and control cells, by visual analysis on the UCSC browser (Karolchik et al., 2014) to identify consistent splicing changes that depend on RBMX expression. The triplicate RNA-seq samples were further analysed for splicing variations using SUPPA2 (Trincado et al., 2018), which identified 6702 differential splicing isoforms with p<0.05. Predicted splicing changes were confirmed by visual inspection of RNA-seq reads using the UCSC (Karolchik et al., 2014) and IGV (Robinson et al., 2011) genome browsers. Identification of common splicing changes between RBMX-depleted MDA-MB-231 and HEK293 cells was done by comparing data from this study with data from GSE74085 (Liu et al., 2017). For comparative analysis, a negative set of cassette exons that were non-responsive to RBMX depletion were those where every splice junction had an absolute dPSI of 2% or less in two of the knockdown experiments analysed.

iCLIP

Request a detailed protocol

iCLIP experiments were performed on triplicate samples in RBMX-FLAG expressing Flp-In HEK293 cells using the protocol described in Huppertz et al., 2014. Briefly, cells were grown in 10 cm tissue culture dishes and irradiated with 400 mJ cm−2 ultraviolet-C light on ice, lysed, and sonicated using Diagenode Bioruptor Pico sonicator for 10 cycles with alternating 30 s on/off at low intensity and 1 mg of protein was digested with 4 U of Turbo DNase (Ambion, AM2238) and 0.28 U/ml (low) or 2.5 U/ml (high) of RNAse I (Thermo Scientific, EN0602). The digested lysates were immunoprecipitated with Protein G Dynabeads (Invitrogen, #10003D) and either 5 μg anti-FLAG antibody (Sigma-Aldrich, F1804) or 5 μg IgG (Santa Cruz biotechnology, sc-2025). Subsequently, a pre-adenylated adaptor L3-IR-App (Zarnegar et al., 2016) was ligated to the 3ʹ of the RNA fragments. The captured Protein-RNA complexes were visualised using Odyssey LI-COR CLx imager scanning in both the 700 nm and 800 nm channels. The RNA bound to the proteins was purified, and reverse transcribed with barcoded RT oligos complementary to the L3 adaptor. The cDNAs were purified using Agencourt AMPure XP beads (Beckman Coulter, A63880), circularised, and linearised by PCR amplification. The libraries were gel purified and sequenced on Illumina NextSeq 500. All iCLIP sequencing read analysis was performed on the iMaps webserver (imaps.goodwright.com) using standardised icount demultiplex and analyse work flow. Briefly, reads were demultiplexed using the experimental barcodes, UMIs (unique molecular identifiers) were used to remove PCR duplicates, and reads were mapped to the human genome sequence (version hg38/GRCh37) using STAR (Dobin et al., 2013). Crosslinked sites were identified on the iMAPS platform and the iCount group analysis workflow was used to merge the replicate samples. For enrichment analysis of RBMX iCLIP around cassette exons we compared the number of exons that contained iCLIP binding events that were regulated by RBMX (either repressed or activated) versus non-responsive RBMX cassette exons sets (defined above) in each of the following regions: the proximal intronic region within 300 nt upstream of the 3ʹ splice site, the proximal intronic region within 300 nt downstream of the 5ʹ splice site, and the splice site proximal exonic regions within 50 nt of the 3ʹ splice site or the 5ʹ splice site.

K-mer enrichment analysis

Request a detailed protocol

K-mer motif enrichment was performed with the z-score approach using the kmer_enrichment.py script from the iCLIPlib suite of tools (https://github.com/sudlab/iCLIPlib, copy archived at Sudbery et al., 2022). All transcripts for each non-overlapping protein-coding gene from the Ensembl v.105 annotations were merged into a single transcript, used for this analysis, using cgat gtf2gtf --method=merge-transcripts (Sims et al., 2014). Each crosslinked base from the merged replicate bam file was extended 15 nucleotides in each direction. For every hexamer, the number of times a crosslink site overlaps a hexamer start position was counted within the gene and then summed across all genes. This occurrence was also calculated across 100 randomisations of the crosslink positions within genes. The z-score was thus calculated for each hexamer as (occurrence – occurrence in randomised sequences)/standard deviation of occurrence in randomised sequences. For motif enrichment analysis within ultra-long internal exons, we compared hexamer occurrence within the set of internal exons from Ensembl v.105 mRNA canonical transcripts of 1000 nt or more and compared those to internal exons of less than 1000 nt and calculated a z-score for each hexamer. A similar analysis was done by stratifying the set of ultra-long internal exons to those with RBMX binding or splicing regulation compared to those with no evidence of RBMX activity.

Exon size analysis

Request a detailed protocol

Analyses of exon sizes from RNA-seq data (Figures 2D and 4D) were used using GraphPad Prism 9.5.0. Annotations of all human exons related to position and size were downloaded from Ensembl Genes v.105 (http://www.ensembl.org/biomart/). Selection of exons expressed in HEK293 was performed using data from control RNA-seq samples of the dataset GSE74085 (Liu et al., 2017), subsequently filtered to focus on mRNA exons using biomaRt v.2.52.0 (Durinck et al., 2005). Size of the internal mRNA exons containing RBMX-regulated splicing patterns was annotated using IGV (Robinson et al., 2011). iCLIP tags were extended to 80 nt sequences centered at the crosslinked site, and annotated within human exons using ChIPseeker v.1.32.0 (Yu et al., 2015) and Ensembl Genes v.105. iCLIP tags present in mRNA exons were filtered using biomaRt v.2.52.0 (Durinck et al., 2005). iCLIP-containing exons were listed once, independently of the number of tags or tag score, and filtered to isolate internal exons using the annotations from Ensembl Genes v.105. Plots were created using ggplot2 v.3.3.6. (Wickham, 2016) on R v.4.2.1. Statistical analyses to compare exon length distributions between samples were performed with Wilcoxon Rank Sum and Kruskal-Wallis tests using base R stats package v.4.2.1 and pseudorank v.1.0.1 (Happ et al., 2020). Significant enrichment of ultra-long exons in RBMX-regulated and bound exons was tested using the ‘N-1’ Chi-squared test (Campbell, 2007) on the MedCalc Software version 20.218.

Gene ontology analyses

Request a detailed protocol

Gene ontology analyses were performed in R v.4.2.1 using GOstats v.2.62.0 (Falcon and Gentleman, 2007) except for [Figure 3—figure supplement 1A] for which clusterProfiler::enrichGO v.4.4.4 (Yu et al., 2012) was used. Entrez annotations were obtained with biomaRt v.2.52.0 (Durinck et al., 2005). Read counts from control treated HEK293 cells (Liu et al., 2017) were used to isolate genes expressed in HEK293 cells. Gene ontology analyses for Figure 3A were performed for ultra-long (>1000 bp) exons bound or regulated by RBMX against all genes expressed in HEK293 cells that contain ultra-long exons. The Bioconductor annotation data package org.Hs.eg.db v.3.15.0 was used as background for GOBP terms. p-values were adjusted by false discovery rate using the base R stats package v.4.2.1, except for [Figure 3—figure supplement 1A] for which the default Benjamini-Hochberg method was used while running enrichGO. Significantly enriched GOBP pathways were filtered with a p-value cut-off of 0.05. Redundant terms identified with GOstats were removed using Revigo (Supek et al., 2011) with SimRel similarity measure against human genes eliminating terms with dispensability score above 0.5. The dot plots were produced using ggplot2 v.3.3.6 (Wickham, 2016) focussing on representative terms associated with at least 5% of the initial gene list. Full GOBP lists can be found in Figure 3—source data 1.

Comet assay

Request a detailed protocol

The comet assay was performed using the Abcam Comet Assay kit (ab238544) according to the manufacturer’s instructions. Briefly U-2 OS cells transfected with RBMX siRNA or control siRNA were harvested after 72 hr, and 1×105 cells were mixed with cold PBS. Cells in PBS were mixed with low-melting comet agarose (1/10) and layered on the glass slides pre-coated with low-melting comet agarose. The slides were lysed in 1 X lysis buffer (pH10.0, Abcam Comet Assay kit) for 48 hr at 4 °C, immersed in Alkaline solution (300 mM NaOH, pH >13, 1 mM EDTA) for 30 min at 4 °C in the dark and then electrophoresed in Alkaline Electrophoresis Solution (300 mM NaOH, pH >13, 1 mM EDTA) at 300 mA, 1 volt/cm for 20 min. The slide was then washed in pre-chilled DI H2O for 2 min, fixed in 70% ethanol for 5 min, and stained with 1 X Vista Green DNA Dye (1/10000 in TE Buffer (10 mM Tris, pH 7.5, 1 mM EDTA), Abcam Comet Assay kit) for 15 min and visualised under fluorescence microscopy Zeiss AxioImager (System 3). Comet quantification was performed using OpenComet (Gyori et al., 2014).

RNA extraction and cDNA synthesis for transcript isoform analysis

Request a detailed protocol

RNA was extracted using standard TRIzol RNA extraction (Invitrogen, #15596026) following the manufacturer’s instructions. cDNA was synthesised from 500 ng total RNA using SuperScript VILO cDNA synthesis kit (Invitrogen #11754050) following the manufacturer’s instructions. To analyse the splicing profiles of the alternative events primers were designed using Primer 3 Plus (Untergasser et al., 2012), and the predicted PCR products were confirmed using the UCSC In-Silico PCR tool. ETAA1 transcript isoform containing the long exon 5 was amplified by RT-PCR using primers 5ʹ-GCTGGACATGTGGATTGGTG-3ʹ and 5ʹ-GTGCTCCAAAAAGCCTCTGG-3ʹ, while ETAA1 transcript isoform containing the short exon 5 was amplified using primers 5ʹ-GCTGGACATGTGGATTGGTG-3ʹ and 5ʹ-GTGGGAGCTGCATTTACAGATG-3ʹ. RT-PCR with this second primer pair could in principle amplify also a 2313 bp product from the ETAA1 transcript isoform containing the long exon 5, however, PCR conditions were chosen to selectively analyse shorter fragments. REV3L 5ʹ-TCACTGTGCAGAAATACCCAC-3ʹ, 5ʹ-AGGCCACGTCTACAAGTTCA-3ʹ, 5ʹ-ACATGGGAAGAAAGGGCACT-3ʹ. ATRX 5ʹ-TGAAACTTCATTTTCAACCAAATGCTC-3ʹ and 5ʹ-ATCAAGGGGATGGCAGCAG-3ʹ All PCR reactions were performed using GoTaq G2 DNA polymerase kit from Promega following the manufacturer’s instructions. All PCR products were examined using the QIAxcel capillary electrophoresis system 100 (Qiagen). Statistical analyses were performed using GraphPad Prism 9.5.0.

Western blot analyses

Request a detailed protocol

Harvested cells treated with either control siRNA or siRNA against RBMX were resuspended in 100 mM Tris-HCL, 200 mM DTT, 4% SDS, 20% Glycerol, 0.2% Bromophenol blue, then sonicated (Sanyo Soniprep 150) and heated to 95 °C for 5 min. Protein separation was performed by SDS-PAGE. Proteins were then transferred to a nitrocellulose membrane, incubated in blocking buffer (5% Milk in 2.5% TBS-T), and stained with primary antibodies diluted in blocking buffer to the concentrations indicated below, at 4 °C overnight. After incubation, the membranes were washed three times with TBS-T and incubated with the secondary antibodies for 1 hr at room temperature. Detection was carried out using the Clarity Western ECL Substrate (Cytiva, RPN2232) and developed using medical X-ray film blue film in an X-ray film processor developer. The following primary antibodies were used at the concentrations indicated: anti-RBMX (Cell Signalling, D7C2V) diluted 1:1000, anti-ETAA1 (Sigma, HPA035048) diluted 1:1000, anti-Tubulin (Abcam, ab18251) diluted 1:2000, anti-GAPDH (Abcepta, P04406) diluted 1:2000, and anti-FLAG (Sigma, F1804) diluted 1:2000.

Minigene construction and validation

Request a detailed protocol

A genomic region containing ETAA1 exon 5 and flanking intronic sequences were PCR amplified from human genomic DNA using the primers 5ʹ-AAAAAAAAACAATTGAGTTAAGACTTTTCAGCTTTTCTGA-3ʹ and 5ʹ-AAAAAAAAACAATTGAGTGCTGGGAAAGAATTCAATGT-3ʹ and cloned into pXJ41 (Bourgeois et al., 1999). Splicing patterns were monitored after transfection into HEK293 cells. RNA was extracted with TRIzol (Invitrogen, #15596026) and analysed using a One Step RT-PCR kit (Qiagen, #210210) following manufacturer’s instructions. RT–PCR experiments used 100 ng of RNA in a 5 μl reaction using a multiplex RT-PCR using primers: 5ʹ-GCTGGACATGTGGATTGGTG-3ʹ, 5ʹ-GTGGGAGCTGCATTTACAGATG-3ʹ and 5ʹ-GTGCTCCAAAAAGCCTCTGG-3ʹ. Reactions were analysed and quantified using the QIAxcel capillary electrophoresis system 100 (Qiagen).

Branchpoint analysis

Request a detailed protocol

Using the RNA from the long minigene transfections with RBMX and RBMXΔRRM, total RNA was extracted using TRIZOL reagent (Life Technologies) following the standard manufacturer’s instructions, RNA concentration was quantified by NanoDrop UV-Vis spectrophotometer and treated with DNase I (Invitrogen, Am1906). 1 μg of purified RNA was reverse transcribed with a SuperScript III Reverse Transcriptase (Invitrogen, #18080093) using ETAA1 DBR R1 RT-PCR primer 5′-AAGTTCTTCTTCTTGACTTTGTGTT-3′ and treated with RNaseH (New England Biolabs, M0297S). 1 μl of the cDNA was used for PCR amplification reactions using using GoTaq G2 DNA Polymerase (Promega, #M7845) in the standard 25 µl reaction following the manufacturer’s instructions. PCR amplification was carried out using two different primer sets ETAA1 DBR R2 5′-GCTCTTGAATCACATCTAGCTCT-3′ and ETAA1 DBR F1 5′-AGCCAAACTAACTCAGCAACA-3′, ETAA1 DBR R2 5′-GCTCTTGAATCACATCTAGCTCT-3′ and ETAA1 DBR F2 5′-AGCATTTGAATCCAGGCAGC-3′ with 18 cycles of amplification at an annealing temperature of 56 °C. PCR products were sub-cloned into the pGEM-T-Easy vector (Promega, A1360) using manufacture instructions. Plasmids were subjected to Sanger sequencing (Source BioScience) and the sequences were checked with BioEdit (Hall, 1999) and aligned to the genome with UCSC (Karolchik et al., 2014).

Data availability

The data discussed in this publication have been deposited in NCBI’s Gene Expression Omnibus (Edgar et al., 2002) and are accessible through GEO series accession number GSE233498. Previously published GSE74085 data was also accessed from Gene Expression Omnibus.

The following data sets were generated
    1. Smith G
    (2023) NCBI Gene Expression Omnibus
    ID GSE233498. An anciently diverged family of RNA binding proteins maintain correct splicing of ultra-long exons through cryptic splice site repression.
    https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE233498
The following previously published data sets were used
    1. Liu N
    2. Parisien M
    3. Dai Q
    4. Zhou K
    5. Diatchenko L
    6. Pan T
    (2017) NCBI Gene Expression Omnibus
    ID GSE74085. N6-methyladenosine alters RNA structure to regulate binding of a low-complexity protein.
    https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE74085

References

    1. Black DL
    (1995)
    Finding splice sites within a wilderness of RNA
    RNA 1:763–771.

Article and author information

Author details

  1. Chileleko Siachisumo

    Biosciences Institute, Faculty of Medical Sciences, Newcastle University, Newcastle, United Kingdom
    Contribution
    Investigation, Writing – original draft
    Contributed equally with
    Sara Luzzi and Saad Aldalaqan
    Competing interests
    No competing interests declared

  2. Sara Luzzi

    Biosciences Institute, Faculty of Medical Sciences, Newcastle University, Newcastle, United Kingdom
    Contribution
    Conceptualization, Funding acquisition, Investigation, Writing – original draft
    Contributed equally with
    Chileleko Siachisumo and Saad Aldalaqan
    For correspondence
    Sara.Luzzi@newcastle.ac.uk
    Competing interests
    No competing interests declared
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-6337-7495

  3. Saad Aldalaqan

    Biosciences Institute, Faculty of Medical Sciences, Newcastle University, Newcastle, United Kingdom
    Contribution
    Investigation
    Contributed equally with
    Chileleko Siachisumo and Sara Luzzi
    Competing interests
    No competing interests declared

  4. Gerald Hysenaj

    Biosciences Institute, Faculty of Medical Sciences, Newcastle University, Newcastle, United Kingdom
    Contribution
    Investigation
    Competing interests
    No competing interests declared

  5. Caroline Dalgliesh

    Biosciences Institute, Faculty of Medical Sciences, Newcastle University, Newcastle, United Kingdom
    Contribution
    Investigation, Writing – review and editing
    Competing interests
    No competing interests declared

  6. Kathleen Cheung

    Bioinformatics Support Unit, Faculty of Medical Sciences, Newcastle University, Newcastle, United Kingdom
    Contribution
    Formal analysis
    Competing interests
    No competing interests declared

  7. Matthew R Gazzara

    Department of Genetics, Perelman School of Medicine, University of Pennsylvania, Phildelphia, United States
    Contribution
    Investigation, Writing – review and editing
    Competing interests
    No competing interests declared

  8. Ivaylo D Yonchev

    School of Biosciences, University of Sheffield, Sheffield, United Kingdom
    Contribution
    Investigation, Writing – review and editing
    Competing interests
    No competing interests declared

  9. Katherine James

    School of Computing, Newcastle University, Newcastle, United Kingdom
    Contribution
    Formal analysis
    Competing interests
    No competing interests declared

  10. Mahsa Kheirollahi Chadegani

    Biosciences Institute, Faculty of Medical Sciences, Newcastle University, Newcastle, United Kingdom
    Contribution
    Resources, Methodology
    Competing interests
    No competing interests declared

  11. Ingrid E Ehrmann

    Biosciences Institute, Faculty of Medical Sciences, Newcastle University, Newcastle, United Kingdom
    Contribution
    Investigation, Writing – review and editing
    Competing interests
    No competing interests declared

  12. Graham R Smith

    Bioinformatics Support Unit, Faculty of Medical Sciences, Newcastle University, Newcastle, United Kingdom
    Contribution
    Data curation, Writing – review and editing
    Competing interests
    No competing interests declared

  13. Simon J Cockell

    Bioinformatics Support Unit, Faculty of Medical Sciences, Newcastle University, Newcastle, United Kingdom
    Contribution
    Formal analysis
    Competing interests
    No competing interests declared
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-6831-9806

  14. Jennifer Munkley

    Biosciences Institute, Faculty of Medical Sciences, Newcastle University, Newcastle, United Kingdom
    Contribution
    Supervision, Investigation
    Competing interests
    No competing interests declared

  15. Stuart A Wilson

    School of Biosciences, University of Sheffield, Sheffield, United Kingdom
    Contribution
    Supervision, Writing – review and editing
    Competing interests
    No competing interests declared

  16. Yoseph Barash

    Department of Genetics, Perelman School of Medicine, University of Pennsylvania, Phildelphia, United States
    Contribution
    Supervision, Investigation, Writing – review and editing
    Competing interests
    No competing interests declared

  17. David J Elliott

    Biosciences Institute, Faculty of Medical Sciences, Newcastle University, Newcastle, United Kingdom
    Contribution
    Conceptualization, Supervision, Funding acquisition, Investigation, Project administration, Writing – review and editing, Writing – original draft
    For correspondence
    David.Elliott@ncl.ac.uk
    Competing interests
    No competing interests declared
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-6930-0699

Funding

Biotechnology and Biological Sciences Research Council (BB/S008039/1)

  • Caroline Dalgliesh
  • David J Elliott

Biotechnology and Biological Sciences Research Council (BB/W002019/1)

  • Sara Luzzi
  • Caroline Dalgliesh
  • Ingrid E Ehrmann
  • David J Elliott

Biotechnology and Biological Sciences Research Council (Newcastle Liverpool Durham BBSRC Doctoral Training Partnership (BB/M011186/1))

  • Chileleko Siachisumo

Biotechnology and Biological Sciences Research Council (BB/P006612/1)

  • Ingrid E Ehrmann
  • David J Elliott

King Fahad Medical City

  • Saad Aldalaqan

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Acknowledgements

This work was supported by the Biotechnology and Biological Sciences Research Council (BBSRC) (grants BB/S008039/1, BBW002019/1, and BB/P006612/1), and by the JGW Patterson Foundation. Saad Aldalaqan was supported by a PhD studentship from the King Fahad Medical City. Chileleko Siachisumo was supported by the Newcastle Liverpool Durham BBSRC Doctoral Training Partnership (BB/M011186/1).

Version history

  1. Sent for peer review:
  2. Preprint posted:
  3. Reviewed Preprint version 1:
  4. Reviewed Preprint version 2:
  5. Version of Record published:

Cite all versions

You can cite all versions using the DOI https://doi.org/10.7554/eLife.89705. This DOI represents all versions, and will always resolve to the latest one.

Copyright

© 2023, Siachisumo, Luzzi, Aldalaqan et al.

This article is distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 692
    views
  • 24
    downloads
  • 0
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Chileleko Siachisumo
  2. Sara Luzzi
  3. Saad Aldalaqan
  4. Gerald Hysenaj
  5. Caroline Dalgliesh
  6. Kathleen Cheung
  7. Matthew R Gazzara
  8. Ivaylo D Yonchev
  9. Katherine James
  10. Mahsa Kheirollahi Chadegani
  11. Ingrid E Ehrmann
  12. Graham R Smith
  13. Simon J Cockell
  14. Jennifer Munkley
  15. Stuart A Wilson
  16. Yoseph Barash
  17. David J Elliott
(2024)
An anciently diverged family of RNA binding proteins maintain correct splicing of a class of ultra-long exons through cryptic splice site repression
eLife 12:RP89705.
https://doi.org/10.7554/eLife.89705.3

Share this article

https://doi.org/10.7554/eLife.89705

Categories and tags

Research organism

Further reading

    1. Chromosomes and Gene Expression

    An ancient germ cell-specific RNA-binding protein protects the germline from cryptic splice site poisoning

    Ingrid Ehrmann, James H Crichton ... David J Elliott
    Research Article

    Male germ cells of all placental mammals express an ancient nuclear RNA binding protein of unknown function called RBMXL2. Here we find that deletion of the retrogene encoding RBMXL2 blocks spermatogenesis. Transcriptome analyses of age-matched deletion mice show that RBMXL2 controls splicing patterns during meiosis. In particular, RBMXL2 represses the selection of aberrant splice sites and the insertion of cryptic and premature terminal exons. Our data suggest a Rbmxl2 retrogene has been conserved across mammals as part of a splicing control mechanism that is fundamentally important to germ cell biology. We propose that this mechanism is essential to meiosis because it buffers the high ambient concentrations of splicing activators, thereby preventing poisoning of key transcripts and disruption to gene expression by aberrant splice site selection.

    1. Chromosomes and Gene Expression

    Transcription factor condensates, 3D clustering, and gene expression enhancement of the MET regulon

    James Lee, Leman Simpson ... Lu Bai
    Research Article

    Some transcription factors (TFs) can form liquid–liquid phase separated (LLPS) condensates. However, the functions of these TF condensates in 3-Dimentional (3D) genome organization and gene regulation remain elusive. In response to methionine (met) starvation, budding yeast TF Met4 and a few co-activators, including Met32, induce a set of genes involved in met biosynthesis. Here, we show that the endogenous Met4 and Met32 form co-localized puncta-like structures in yeast nuclei upon met depletion. Recombinant Met4 and Met32 form mixed droplets with LLPS properties in vitro. In relation to chromatin, Met4 puncta co-localize with target genes, and at least a subset of these target genes is clustered in 3D in a Met4-dependent manner. A MET3pr-GFP reporter inserted near several native Met4-binding sites becomes co-localized with Met4 puncta and displays enhanced transcriptional activity. A Met4 variant with a partial truncation of an intrinsically disordered region (IDR) shows less puncta formation, and this mutant selectively reduces the reporter activity near Met4-binding sites to the basal level. Overall, these results support a model where Met4 and co-activators form condensates to bring multiple target genes into a vicinity with higher local TF concentrations, which facilitates a strong response to methionine depletion.

    1. Chromosomes and Gene Expression
    2. Immunology and Inflammation

    Dynamic chromatin architecture identifies new autoimmune-associated enhancers for IL2 and novel genes regulating CD4+ T cell activation

    Matthew C Pahl, Prabhat Sharma ... Andrew D Wells
    Research Article

    Genome-wide association studies (GWAS) have identified hundreds of genetic signals associated with autoimmune disease. The majority of these signals are located in non-coding regions and likely impact cis-regulatory elements (cRE). Because cRE function is dynamic across cell types and states, profiling the epigenetic status of cRE across physiological processes is necessary to characterize the molecular mechanisms by which autoimmune variants contribute to disease risk. We localized risk variants from 15 autoimmune GWAS to cRE active during TCR-CD28 co-stimulation of naïve human CD4+ T cells. To characterize how dynamic changes in gene expression correlate with cRE activity, we measured transcript levels, chromatin accessibility, and promoter–cRE contacts across three phases of naive CD4+ T cell activation using RNA-seq, ATAC-seq, and HiC. We identified ~1200 protein-coding genes physically connected to accessible disease-associated variants at 423 GWAS signals, at least one-third of which are dynamically regulated by activation. From these maps, we functionally validated a novel stretch of evolutionarily conserved intergenic enhancers whose activity is required for activation-induced IL2 gene expression in human and mouse, and is influenced by autoimmune-associated genetic variation. The set of genes implicated by this approach are enriched for genes controlling CD4+ T cell function and genes involved in human inborn errors of immunity, and we pharmacologically validated eight implicated genes as novel regulators of T cell activation. These studies directly show how autoimmune variants and the genes they regulate influence processes involved in CD4+ T cell proliferation and activation.